In multiple myeloma, the supporting effect of galectin-3 was reduced, and malignant cells were sensitized to chemotherapeutic drugs, by treatment with two agents: galectin-3 antagonist GCS-100 and an N-terminally truncated form of galectin-3 (124). This evidence concerns the gene LGALS3 and plasma cell myeloma.